Efter fornyet overvejelse i marts 2007 ophævede CHMP sine forbehold vedrørende cytokinfrigivelsessyndrom og blodtryksforhøjelse, da disse kan håndteres ved behandlingen.
In March 2007, following the re-examination, the CHMP removed their concern regarding the cytokine release syndrome and hypertension, as these would be manageable in clinical practice.